Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Proficio Capital Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth ...

Shares of 908 Devices (NASDAQ:MASS) climbed ~71% in the premarket on Tuesday after Repligen (NASDAQ:RGEN) offered $70M in cash to acquire the company’s bioprocessing analytics portfolio. As part of ...

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a report ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Repligen (NasdaqGS:RGEN) with a In-Line ...

Repligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains.

GAAP gross margin declined to 23.2% from 47.1% a year prior due to restructuring costs. Repligen is a leader in the development and production of innovative technologies used in the manufacturing ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...